PE-conjugated Anti-CD19(tafasitamab biosimilar) mAb

Cat. No. BME100683P

PRODUCT INFORMATION

Uniprot ID	P15391
Common Name	ICP-B04;ICP B04;MOR 208;MOR208;MOR-208;XENP-5574;XENP5574;XENP 5574;XmAb-5574;XmAb5574;XmAb 5574
Conjugate	PE-conjugated
Synonyms	CD19;B4;CVID3;MGC12802
Applications	Flow Cyt
Recommended Dilutions	1μl/test
Formulation & Reconstitution	Liquid□PBS with,0.18%BSA□0.1%Proclin300
Host Species	N/A
IgG type	IgG1
Reactivity	Human
Target	CD19
Description	PE-conjugated Anti-CD19(tafasitamab biosimilar) mAb
Delivery	In Stock
Storage&Shipping	Store at 2°C-8°C for 6 months
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only

DIMABIO CONFIDENTIAL

Address: Wuhan institute of Biotechnology B7, Biolake No.666 Gaoxin Road, Wuhan, Hubei, China
Telephone: +1 2409940618(USA)
/+86-18062749453(China)
/+86-400-006-0995(China)

Email: info@dimabio.com
Website: www.dimabio.com

PE-conjugated Anti-CD19(tafasitamab biosimilar) mAb

Cat. No. BME100683P




Figure 1. Flow cytometry analysis with 1μl/test PE-conjugated Anti-CD19(tafasitamab biosimilar) mAb on Raji cells (Blue histogram)or 293T cells (Red histogram).

DIMABIO CONFIDENTIAL

Address: Wuhan institute of Biotechnology B7, Biolake No.666 Gaoxin Road, Wuhan, Hubei, China
Telephone: +1 2409940618(USA)
/+86-18062749453(China)
/+86-400-006-0995(China)

Email: info@dimabio.com
Website: www.dimabio.com